Literature DB >> 16791442

Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.

Y-F Xu1, Y-Q Zhang, X-M Xu, G-X Song.   

Abstract

Papillomaviruses (PVs) are simple double-strand DNA viruses whose virion shells are T = 7 icosahedrons and composed of major capsid protein L1 and minor capsid protein L2.L1 alone or together with L2 can self-assemble into virus-like particles (VLPs) when expressed in eukaryotic or prokaryotic expression systems. Although the VLPs lack the virus genome DNA, their morphological and immunological characteristics are very similar to those of nature papillomaviruses. PV VLP vaccination can induce high titers of neutralizing antibodies and can effectively protect animals or humans from PV infection. Moreover, PV VLPs have been good candidates for vehicles to deliver epitopes or genes to target cells. They are widely used in the fields of vaccine development, neutralizing antibody detection, basic virologic research on papillomaviruses, and human papillomavirus (HPV) screening. Besides the structural biology and immunological basis for PV VLPs used as vehicles to deliver epitopes or genes, this review details the latest findings on chimeric papillomavirus VLPs and papillomavirus pseudoviruses, which are two important forms of PV VLPs used to transfer epitopes or genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791442     DOI: 10.1007/s00705-006-0798-8

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  Protein transfer into human cells by VSV-G-induced nanovesicles.

Authors:  Philippe-Emmanuel Mangeot; Sandra Dollet; Mathilde Girard; Claire Ciancia; Stéphane Joly; Marc Peschanski; Vincent Lotteau
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

Review 2.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

3.  Characterization of an RNA aptamer against HPV-16 L1 virus-like particles.

Authors:  Ana Gabriela Leija-Montoya; María Luisa Benítez-Hess; Julia Dolores Toscano-Garibay; Luis Marat Alvarez-Salas
Journal:  Nucleic Acid Ther       Date:  2014-08-11       Impact factor: 5.486

Review 4.  Biology of human papillomavirus-related oropharyngeal cancer.

Authors:  Jason D Howard; Christine H Chung
Journal:  Semin Radiat Oncol       Date:  2012-07       Impact factor: 5.934

5.  Yeast-expressed bacteriophage-like particles for the packaging of nanomaterials.

Authors:  Janis Freivalds; Svetlana Kotelovica; Tatyana Voronkova; Velta Ose; Kaspars Tars; Andris Kazaks
Journal:  Mol Biotechnol       Date:  2014-02       Impact factor: 2.695

6.  Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Authors:  Hee-Jung Lee; Jong Kwang Yoon; Yoonki Heo; Hansam Cho; Yeondong Cho; Yongdae Gwon; Kang Chang Kim; Jiwon Choi; Jae Sung Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

7.  Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.

Authors:  Dinesh Adhikary; Uta Behrends; Regina Feederle; Henri-Jacques Delecluse; Josef Mautner
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

8.  Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

Authors:  Wolfgang W Leitner; Matthew C Baker; Thomas L Berenberg; Michael C Lu; P Josef Yannie; Mark C Udey
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

Review 9.  Mechanisms of cell entry by human papillomaviruses: an overview.

Authors:  Caroline A J Horvath; Gaëlle A V Boulet; Virginie M Renoux; Philippe O Delvenne; John-Paul J Bogers
Journal:  Virol J       Date:  2010-01-20       Impact factor: 4.099

10.  Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions.

Authors:  Adolfo Pedroza-Saavedra; Angelica Nallelhy Rodriguez-Ocampo; Azucena Salazar-Piña; Aislinn Citlali Perez-Morales; Lilia Chihu-Amparan; Minerva Maldonado-Gama; Aurelio Cruz-Valdez; Fernando Esquivel-Guadarrama; Lourdes Gutierrez-Xicotencatl
Journal:  Vaccines (Basel)       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.